Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy

Research output: Contribution to journalArticle


Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated. Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion). Results: Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome. Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.

Original languageEnglish
Pages (from-to)2569-2578
Number of pages10
JournalFuture Oncology
Issue number16
Publication statusPublished - Dec 1 2014



  • CINV
  • dexamethasone
  • high-dose chemotherapy
  • nausea
  • vomiting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this